[{"orgOrder":0,"company":"Bial","sponsor":"Recipharm AB","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bial \/ Bial","highestDevelopmentStatusID":"12","companyTruncated":"Bial \/ Bial"},{"orgOrder":0,"company":"Bial","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"PORTUGAL","productType":"Small molecule","year":"2021","type":"Termination","leadProduct":"Eslicarbazepine Acetate","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bial \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Bial \/ Eisai"},{"orgOrder":0,"company":"Bial","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Bial \/ Bial","highestDevelopmentStatusID":"12","companyTruncated":"Bial \/ Bial"},{"orgOrder":0,"company":"Bial","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"PORTUGAL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BIA 28-6156","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bial \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bial \/ Not Applicable"},{"orgOrder":0,"company":"Bial","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"PORTUGAL","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Opicapone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bial \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Bial \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Bial","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"PORTUGAL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BIA 28-6156","moa":"Beta-GCase","graph1":"Neurology","graph2":"Phase II","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bial \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bial \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Bial

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : BIA 28-6156 is a first-in-class, oral small molecule, allosteric activator of beta-glucocerebrosidase , in development for Parkinson's disease who have a mutation in the GBA1.

                          Product Name : BIA 28-6156

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 07, 2025

                          Lead Product(s) : BIA 28-6156

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Under the agreement, Amneal will have exclusive rights to market and distribute ONGENTYS (opicapone), a highly-selective COMT inhibitor, which is approved by USFDA as an add-on treatment to carbidopa/levodopa in patients with Parkinson’s disease experi...

                          Product Name : Ongentys

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 07, 2023

                          Lead Product(s) : Opicapone

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Amneal Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : BIA 28-6156 is an allosteric activator of the enzyme beta-glucocerebrosidase (GCase) for the treatment of patients with Parkinson's disease (PD) who have a mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).

                          Product Name : BIA 28-6156

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 25, 2023

                          Lead Product(s) : BIA 28-6156

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Under the terms of the agreement, BIAL will be responsible for regulatory approvals and submissions, including interactions with the European Medicines Agency (EMA) for APL-130277, which is currently in Phase 3 clinical development in Europe.

                          Product Name : Kynmobi

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 02, 2021

                          Lead Product(s) : Apomorphine Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Recipient : Sunovion Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : BIAL takes the lead for the marketing and distribution of Zebinix® (eslicarbazepine acetate) in Europe. Eslicarbazepine acetate is a once-daily anti-epileptic used to treat epilepsy patients with focal seizures (partial-onset seizures).

                          Product Name : Zebinix

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 17, 2021

                          Lead Product(s) : Eslicarbazepine Acetate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Eisai

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          blank

                          06

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The new agreement provides both companies with a long-term partnership that will ensure continued supply for patients across the globe. Opicapone (Ongentys) is approved in Europe, USA, South Korea, Taiwan, Australia and Japan.

                          Product Name : Ongentys

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 01, 2020

                          Lead Product(s) : Opicapone

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Recipient : Recipharm AB

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank